Abbott Labs Posts Strong First-Quarter Growth
Abbott Labs reports higher earnings from continuing operations, as demand for its nutritional and diagnostic products offset declining sales of the company's medical devices.
Abbott Laboratories
You Know What's Overrated? Retirement
There are several major flaws in the classic "retirement as a goal" scenario, but you're not locked into it. If you've avoided major debt and have an education that allows you the freedom to re-imagine the concept, you could completely change your life.
Abbott Laboratories Recalls 359 Million Diabetes Test Strips
Abbott Laboratories is recalling roughly 359 million blood-sugar test strips for diabetics after the strips turned out to yield falsely low readings.
Abbott Pulls Weight Loss Drug Meridia from Market
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
Baby Formula Recall: Parents Worried In Spite of Doctors' Reassurance
Abbott has recalled 5 million containers of its top-selling powdered baby formula, Similac, after finding beetles at one of its factories. But parents shouldn't panic, the company says. The chances that any beetlejuice actually made it into the formula is slim, and doctors say babies wouldn't be harmed even if it did.
Abbott to Layoff 3,000 Employees Following Solvay Unit Acquisition
Giant U.S. pharmaceutical group Abbott Laboratories is cutting 3,000 jobs, or about 3% of its workforce, following its purchase of Belgian-based Solvay's drugs business.
Should U.S. Regulators Take Meridia Diet Pill Off the Market?
The New England Journal of Medicine called Meridia "another flawed diet pill" -- two weeks before government advisers are scheduled to review the drug -- after a study finds it raises the risk of heart attack and stroke in users with heart problems.
Feds Scrutinize Deals Delaying Generic Drugs
The Feds -- and consumers -- may finally have had it with 'pay-for-delay.' In these deals, generic drug companies that challenge a patent held by a name-brand pharmaceuticals agree to settle by delaying their entry into the market in return for a payment. But regulators are now calling for laws to end the practice.
